What is Element Biosciences?
Element Biosciences operates at the critical intersection of biology, engineering, and data science. The company specializes in the development of advanced genomic sequencing, multiomics, and spatial biology platforms designed to democratize access to high-quality biological data. By prioritizing flexible workflows and integrated analysis solutions, Element Biosciences enables researchers and diagnostic laboratories to accelerate breakthroughs in drug development and precision medicine. Its market position is defined by a commitment to reducing the cost and complexity of biological data generation, thereby empowering scientific discovery across diverse clinical and research applications.
How much funding has Element Biosciences raised?
Element Biosciences has raised a total of $823M across 5 funding rounds:
Series A
$15M
Series B
$80M
Series C
$276M
Series D
$277M
Series E
$175M
Series A (2019): $15M with participation from Venrock and Foresite Capital
Series B (2020): $80M led by JS Capital LLC, Venrock, Foresite Capital, and Fidelity Management & Research Company
Series C (2021): $276M supported by Logos Capital, Janus Henderson Investors, and Meritech Capital Partners
Series D (2024): $277M featuring Samsung Electronics, Wellington Management, Fidelity, and Foresite Capital
Series E (2026): $175M backed by Samsung
Key Investors in Element Biosciences
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data.
Venrock
Founded in 1969, Venrock is a venture capital firm known for its entrepreneurial support, strategic guidance, and long track record of backing successful technology and healthcare ventures.
Fidelity Management & Research Company
Fidelity Investments is a financial services company that provides a broad range of investment, wealth management, and advisory solutions for individual investors and institutions.
What's next for Element Biosciences?
With the successful closure of its latest financing round, Element Biosciences is well-positioned to accelerate its commercial expansion and R&D initiatives. The company is expected to leverage this capital to enhance its multiomics product suite and scale its global distribution network. As the demand for high-resolution biological insights continues to grow within the pharmaceutical and healthcare sectors, Element Biosciences is strategically aligned to capture significant market share. Future growth will likely focus on deepening its integration within clinical diagnostic workflows and expanding its footprint in the rapidly evolving field of spatial biology, ensuring the firm remains at the forefront of the next generation of genomic innovation.
See full Element Biosciences company page
